Health-economic comparison of paricalcitol, calcitriol and Alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis

被引：0
|
作者：
Fiedler, Roman [1 ]
机构：
[1] Univ Halle Wittenberg, Dept Nephrol, Halle, Germany
来源：
CLINICAL DRUG INVESTIGATION | 2007年 / 27卷 / 12期
关键词：
Secondary Hyperparathyroidism; Alfacalcidol; Active Vitamin; National Kidney Foundation; Paricalcitol;
D O I：
10.2165/00044011-200727120-00010
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：865 / 866
页数：2
相关论文
共 50 条
  • [1] Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis
    Roman Fiedler
    Clinical Drug Investigation, 2007, 27 : 865 - 866
  • [2] Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis
    Hubertus Rosery
    Rito Bergemann
    Steven E. Marx
    Axel Boehnke
    Joel Melnick
    Raimund Sterz
    Laura Williams
    Clinical Drug Investigation, 2006, 26 : 629 - 638
  • [3] Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
    Ditte Hansen
    Lisbet Brandi
    Knud Rasmussen
    BMC Nephrology, 10
  • [4] Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
    Sprague, SM
    Llach, F
    Amdahl, M
    Taccetta, C
    Batlle, D
    KIDNEY INTERNATIONAL, 2003, 63 (04) : 1483 - 1490
  • [5] Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients
    Kiattisunthorn, Kraiwiporn
    Wutyam, Kittikarn
    Indranoi, Artit
    Vasuvattakul, Somkiat
    NEPHROLOGY, 2011, 16 (03) : 277 - 284
  • [6] Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol
    Hansen, Ditte
    Rasmussen, Knud
    Pedersen, Susanne M.
    Rasmussen, Lars M.
    Brandi, Lisbet
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (06) : 2263 - 2269
  • [7] Comparison of the Pharmacological Effects of Paricalcitol Versus Calcitriol on Secondary Hyperparathyroidism in the Dialysis Population
    Veceric-Haler, Zeljka
    Romozi, Karmen
    Antonic, Manja
    Benedik, Miha
    Ponikvar, Jadranka Buturovic
    Ponikvar, Rafael
    Knap, Bojan
    THERAPEUTIC APHERESIS AND DIALYSIS, 2016, 20 (03) : 261 - 266
  • [8] Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies
    Zhang, Tong
    Ju, Hongbo
    Chen, Haojun
    Wen, Wen
    THERAPEUTIC APHERESIS AND DIALYSIS, 2019, 23 (01) : 73 - 79
  • [9] Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism
    Llach, F
    Yudd, M
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (05) : S45 - S50
  • [10] Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients
    Rauscher, Sandrine
    Lafrance, Jean-Philippe
    Pichette, Vincent
    Bell, Robert Z.
    Desforges, Katherine
    Lepage, Laurence
    Ouellet, Georges
    Ouimet, Denis
    Leblanc, Martine
    Lamarche, Caroline
    Bezzaoucha, Sarah
    Vallee, Michel
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2017, 49 (02) : 325 - 328
12345